IceCure Medical (ICCM) shareholders back all special meeting items

Rhea-AI Filing Summary

IceCure Medical Ltd. held a Special General Meeting of Shareholders on September 1, 2025, where a quorum was present and voting took place. Shareholders approved all agenda items that had been described in the company’s proxy statement for the meeting, which had been furnished to the SEC on August 1, 2025. The report states that this Form 6-K is incorporated by reference into IceCure Medical’s existing registration statements on Form F-3 and Form S-8, meaning it becomes part of those offering documents from the date of submission.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025 (Report No. 2)

Commission file number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

On September 1, 2025, IceCure Medical Ltd. (the “Company”) convened its Special General Meeting of Shareholders (the “Meeting”).

At the Meeting, a quorum was present and the shareholders of the Company voted upon and approved, all agenda items that were described in the Company’s proxy statement for the Meeting, which were included in Exhibit 99.2 to the Company’s Amendment to Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission (“SEC”) on August 1, 2025 (the “Proxy Statement”).

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-267272 and 333-258660) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587), filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: September 4, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2

FAQ

What did IceCure Medical (ICCM) report in this Form 6-K?

The company reported that it convened a Special General Meeting of Shareholders on September 1, 2025, where all agenda items described in its proxy statement were approved.

What happened at IceCure Medical’s Special General Meeting on September 1, 2025?

A quorum of shareholders was present, and they voted upon and approved all agenda items listed in the proxy statement for the meeting.

Where were the agenda items for IceCure Medical’s special meeting described?

The agenda items were described in the company’s proxy statement for the meeting, included as Exhibit 99.2 to an earlier Form 6-K amendment furnished to the SEC on August 1, 2025.

How is this IceCure Medical Form 6-K used in relation to its registration statements?

This Form 6-K is incorporated by reference into IceCure Medical’s registration statements on Form F-3 and Form S-8, making it part of those documents from the submission date.

Which IceCure Medical registration statements are affected by this Form 6-K?

The report is incorporated into Form F-3 registration numbers 333-267272 and 333-258660, and Form S-8 registration numbers 333-270982, 333-264578, 333-262620, and 333-281587.

Who signed IceCure Medical’s September 2025 Form 6-K?

The report was signed on behalf of IceCure Medical Ltd. by Eyal Shamir, the company’s Chief Executive Officer, dated September 4, 2025.